Hikma Pharmaceuticals PLC HIK shares shed 3.16% to £19.02 Friday, on what proved to be an all-around rough trading session ...

Shares of Hikma Pharmaceuticals PLC HIK inched down 0.05% to £19.14 Wednesday, on what proved to be an all-around rough ...

Worldcategory Dechra, Hikma, M&S and Diploma set to join FTSE 100 August 23, 2023 Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider ...

The FDA approved generic versions of Vyvanse from 11 drugmakers, including U.S.-based drugmakers Mallinckrodt and Viatris, UK-based Hikma Pharmaceuticals, and Indian drugmaker Sun Pharmaceutical ...

With many various solutions on the market, finding the best website design software for your needs is no easy task. To help make your decision easier, Forbes Advisor analyzed the leading options ...

On the downside, Hikma Pharmaceuticals slipped by 0.6%, reversing earlier gains that followed an upgrade to 'buy' from 'hold' by Berenberg. Rightmove dropped 5.03%, retreating after Monday's surge.

Barclays cuts Prudential price target to 1,250 (1,380) pence - 'overweight' Barclays reinitiates Barratt Developments with 'overweight' - price target 641 pence Barclays raises HGCapital Trust to ...

Hikma is offering clindamycin in 5% dextrose injection, in 300mg/50ml, 600mg/50ml and 900mg/50ml doses. The product is available in a vial. Clindamycin in 5% dextrose injection is indicated for ...

New Delhi: To maintain dominance in the global pharmaceutical market and bridge the gap between established and emerging players, Union Minister Jitin Prasada has urged the country’s ...

Also Read: Why Is Jazz Pharmaceuticals Stock Trading Lower ... and emphasized that other narcolepsy treatments are available. Hikma’s generic version of Xyrem only reached the market last ...